title: Uterine pleomorphic rhabdomyosarcoma in a patient receiving tamoxifen therapy.
abstract: BACKGROUND
  Tamoxifen has been used as adjuvant therapy for the treatment of breast cancer. Its use has been associated with the development of proliferative endometrial lesions such as polyps, hyperplasia, and carcinoma. Mesenchymal tumors including malignant mixed mullerian tumors, endometrial stromal sarcomas, adenosarcomas, and leiomyosarcomas have been more recently described with tamoxifen use.
  
  
  METHODS
  This report describes the first case of a pure uterine rhabdomyosarcoma in a patient receiving tamoxifen therapy.
  
  
  CONCLUSIONS
  Although uterine rhabdomyosarcomas are rare tumors and may arise de novo, we discuss the possible role of tamoxifen in the development of these mesenchymal tumors.
authors.affiliation: Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
authors.forename: D H
authors.initials: DH
authors.lastname: Okada
authors.forename: J B
authors.initials: JB
authors.lastname: Rowland
authors.forename: L M
authors.initials: LM
authors.lastname: Petrovic
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000473:pathology; D012208:Rhabdomyosarcoma / Q000139:chemically induced* / Q000473:pathology; D013629:Tamoxifen / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen